Welcome

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.

READ MORE

Paradigm Shift

Repurposing

Established drugs can be repurposed for new clinical indications for unmet medical needs when protected by strong intellectual property. Historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs.

READ MORE

Understanding complexity

Life is complex! For every diagnosis, there are multiple factors and biological interactions involved. We develop therapeutics targeting multiple pathways involved in injury or on the road to disease producing better outcomes for patients.

READ MORE

We develop therapeutics targeting multiple pathways involved in injury

Our focus

Pentosan Polysulphate Sodium (PPS)

We focus on PPS because this FDA approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and respiratory disease.

READ MORE

Inflammation

Inflammation is a complex biological response to injury, infection or allergy, which has short and long term components mediated by factors produced by immune cells.

READ MORE

Recent Highlights

Click here for all ASX announcements.

Paradigm reports Positive Pre-IND meeting with US FDA

21st February 2020

Paradigm Biopharmaceuticals is pleased to announce a positive and informative pre-IND meeting with the US FDA. The meeting took place at the FDA offices in Washington and was attended by several of the Paradigm team and consultants.

READ MORE

All 10 participants in US FDA EAP have commenced treatment

24th March 2020

Paradigm is pleased to announce it has commenced dosing of all ten patients with Zilosul under the FDA approved Expanded Access Program (EAP) in the US.

READ MORE

Paradigm Latest Corporate Presentation

6th April 2020

Paradigm Biopharmaceuticals – latest corporate presentation

READ MORE

Inflammation is a complex biological response to injury, infection or allergy

Key Statistics

Alpharirus

Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.

*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016

Osteoarthritis (OA)

OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.

*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September

Bone Marrow Edema (BME)

Worldwide hip & knee surgical implant market is $16.7 billion, will be $33 billion by 2022. Acute joint injury leads to osteoarthritis.

Bone Marrow Edema (BME)

>50% top ranked skiers have injured knee ligaments (women 5x more susceptible than men)

Research & Development

Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.

READ MORE